Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2015
Multicenter StudyA phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Vismodegib is approved for treatment of advanced basal cell carcinoma. ⋯ Primary efficacy end points were not met (predefined complete histologic clearance rate: >50% in cohorts 1 and 3; >30% in cohort 2). Safety was comparable when dosed continuously versus intermittently. Posttreatment reversibility of vismodegib-related AEs was demonstrated.
-
J. Am. Acad. Dermatol. · Jul 2015
Randomized Controlled Trial Multicenter StudyApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Apremilast works intracellularly to regulate inflammatory mediators. ⋯ Apremilast was effective in moderate to severe plaque psoriasis.
-
J. Am. Acad. Dermatol. · Jul 2015
ReviewPatient safety in procedural dermatology: Part II. Safety related to cosmetic procedures.
Cosmetic procedures are growing in popularity and are associated with unique risks. Considering potential complications and prioritizing patient safety will help practitioners improve outcomes of elective procedures. In part II of this continuing medical education article, we provide a comprehensive review of patient safety in cosmetic procedures, including medical and legal issues surrounding the supervision and training of physician extenders.
-
J. Am. Acad. Dermatol. · Jul 2015
Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Noninvasive treatments are frequently used in treatment of superficial basal cell carcinoma (sBCC) because of better cosmetic results, lower costs, and less burden on health care services when compared with surgical excision. However, probability of treatment failure is higher after noninvasive therapies and may depend on histologic tumor characteristics. ⋯ There seems to be no need to determine tumor thickness or adnexal extension in sBCC before treatment.